Dosing overview

Treating the Adult CF Patient

Marty Solomon, MD, Pulmonologist and Director of the Adult CF Clinic at the University of Alabama at Birmingham, explains what BRONCHITOL® (mannitol) inhalation powder is and how to administer it.

BRONCHITOL® (mannitol) inhalation powder
dosing and administration information1

Inhaler
  • An inhaled short-acting bronchodilator should be administered 5–15 minutes
    before every dose of BRONCHITOL
400 mg twice a day visual
  • The recommended dosage of BRONCHITOL is 400 mg twice a day
  • This requires inhalation of the contents of 10 capsules via the inhaler, twice a day
Day/Night
  • BRONCHITOL should be taken once in the morning and once in the evening
  • The later dose should be taken at least 2–3 hours before bedtime
Calendar
  • The inhaler should be discarded and replaced after 7 days of use
  • If the inhaler needs to be washed, allow it to thoroughly air dry before next use
Personal Items: mobile phone, penwatch
BRONCHITOL Blister Pack and Inhaler

Administer the BRONCHITOL
Tolerance Test before prescribing

This test must always be administered to identify patients who are hyperresponsive to inhaled mannitol. It also allows patients to practice proper inhalation technique under the supervision of a trained healthcare practitioner.

Learn more about the BTT


Click ButtonClick Button

BRONCHITOL is not intended to be used as a rescue medication. Inhaler and blister pack are not actual size and are for representation only. Use an inhaled bronchodilator 5–15 minutes before taking BRONCHITOL.

 
Request Form Icon

Learn more about Chiesi CareDirect®
for additional support

Click ButtonClick Button
Sales Rep Connect

Connect with your local
sales representative

Click ButtonClick Button

Important Safety
Information

BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).

BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.

Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.

Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.

Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.

Please see Full Prescribing Information.

Indication

BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.

Please see Full Prescribing Information.

Reference: 1. BRONCHITOL® (mannitol) inhalation powder Prescribing Information. 2020.